VLA-4 (integrin alpha-4/beta-1)
Assets acting on this target.
- Class
- Small molecule VLA-4 antagonist
- Notes
- verified in session 2026-08-25 (owner-delegated review); source: https://pubmed.ncbi.nlm.nih.gov/22226929/
Assets acting on this target.
1 of 1 assets (1 discontinued)
| Drug | Owner | Mechanism | Indication | Reached | Why it stopped | Source |
|---|---|---|---|---|---|---|
| Firategrast (SB-683699) | GlaxoSmithKline | VLA-4 (integrin alpha-4/beta-1) | Multiple Sclerosis | Ph 2 | GSK's firategrast (immediate-release tablet) program had no trial activity after 2011; all registered firategrast MS studies are completed with none since, consistent with the compound being discontinued. | source ↗ |